https://pmc.ncbi.nlm.nih.gov/articles/PMC3505292/
Here’s the thing
Ath has done the Gold Standard Phase 2 trial .
A double blinded / placebo study with 77 MSA early stage patients .
Results are outstanding . Robust and Stellar.
So we have achieved as our primary trial a double blinded study/placebo and meeting our endpoints..
this alone should get us AA from the FDA
We don’t have to wait until mid year for the results from the open label study to meet with the FDA
We have already proved that Ath 434 is safe and tolerable
Ann: Alterity Completes Last Patient Visit in Open-Label Trial, page-10
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.1¢ | $88.06K | 8.054M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 11330464 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1574126 | 5 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |